Unlike GLP-1s, PCSK9 inhibitors are a near "free lunch." Discovered from a genetic mutation in a population with virtually no heart disease, these drugs dramatically lower bad cholesterol with minimal trade-offs, making them an ideal preventative tool.

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

A lack of representation in genomic data has direct clinical consequences. A deep understanding of European genetics and a poor understanding of other groups has already manifested in less precise medical treatments for non-European populations, undermining the core promise of precision medicine.

Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

Regeneron's genetics engine created so many new targets that it revealed a strategic weakness: two-thirds were intracellular and untreatable with its world-class antibody platform. This success forced the company to "reinvent itself" and invest heavily in new modalities like sRNA and gene therapy to capitalize on its own discoveries.

While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.